Clinical Research Directory
Browse clinical research sites, groups, and studies.
DAOIB for the Treatment of Brain Fog
Sponsor: Chang Gung Memorial Hospital
Summary
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Official title: DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-02-27
Completion Date
2026-06
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Locations (1)
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan